Biodesix (BDSX) Accumulated Expenses (2019 - 2026)

Biodesix (BDSX) has reported Accumulated Expenses for 8 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $5.5 million, up 26.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.5 million (up 26.74% YoY), and the FY2025 annual result was $11.0 million, up 9.63% from the prior year.
• Accumulated Expenses was $5.5 million for Q1 2026 at Biodesix, down from $11.0 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $11.0 million in Q4 2025 and troughed at $747000.0 in Q3 2025.
• Average Accumulated Expenses over 5 years is $5.4 million, with a median of $5.5 million recorded in 2026.
• Year-over-year, Accumulated Expenses soared 923.8% in 2024 and plunged 91.27% in 2025.
• Over 5 years, Accumulated Expenses stood at $4.7 million in 2022, then slumped by 78.96% to $983000.0 in 2023, then jumped by 923.8% to $10.1 million in 2024, then climbed by 9.63% to $11.0 million in 2025, then sank by 49.82% to $5.5 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $5.5 million in Q1 2026, $11.0 million in Q4 2025, and $747000.0 in Q3 2025.